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Serpins (serine protease inhibitors) are a large family of struc-
turally related proteins found in a wide variety of organisms,
including hematophagous arthropods. Protein analyses re-
vealed that Iris, previously described as an immunomodulator
secreted in the tick saliva, is related to the leukocyte elastase
inhibitor and possesses serpin motifs, including the reactive
center loop (RCL), which is involved in the interaction between
serpins and serine proteases. Only serine proteases were inhib-
ited by purified recombinant Iris (rIris), whereas mutants
L339A and A332P were found devoid of any protease inhibitory
activity. The highest Ka was observed with human leukocyte-
elastase, suggesting that elastase-like proteases are the natural
targets of Iris. In addition, mutation M340R completely
changed both Iris substrate specificity and affinity. This likely
identified Met-340 as amino acid P1 in the RCL. The effects of
rIris and its mutants were also tested on primary hemostasis,
blood clotting, and fibrinolysis. rIris increased platelet adhe-
sion, the contact phase-activated pathway of coagulation, and
fibrinolysis times in a dose-dependent manner, whereas rIris
mutant L339A affected only platelet adhesion. Taken together,
these results indicate that Iris disrupts coagulation and fibrinol-
ysis via the anti-proteolytic RCL domain. One or more other
domains could be responsible for primary hemostasis inhibi-
tion. To our knowledge, this is the first ectoparasite serpin that
interferes with both hemostasis and the immune response.
Ticks are blood-sucking arthropods that infest a large variety
of vertebrate hosts (mammals, birds, reptiles, and amphibians)
in many parts of the world (1). To complete their blood meal,
blood-sucking arthropods express a wide range of anti-hemo-
static molecules in their saliva, including vasodilators, inhibi-
tors of the platelet aggregation, and anti-coagulants (2). Tick
saliva and salivary gland extracts are also known to modulate
the host’s defense mechanisms (3–6). Both anti-hemostatic
and immunosuppressive compounds were identified, isolated,
and characterized from soft and hard ticks. These compounds
include histamine-binding proteins, tissue factor pathway
inhibitor-like proteins, anti-thrombin-like proteins, and anti-
complement factors (7–16).
These last years, several laboratories reported the construc-
tion and screening of cDNA libraries from tick salivary glands.
Thus, Das et al. (17) found 14 Ixodes scapularis immunodomi-
nant antigens, whereas Leboulle et al. (18) identified 27mRNA,
the expression of which is specifically induced or up-regulated
during the Ixodes ricinus blood meal. Finally, Ribeiro and co-
workers explored the sialome of the tick I. scapularis (19, 20)
and uncovered a large variety of putative bioactive agents.
These studies all identified some serine protease inhibitors,
containing serpin, kunitz, kazal, or -macroglobulin motifs
(21).
To date,500 serpins have been identified in a large variety
of species, including animals, viruses, and plants. On average,
serpins are 350–400 amino acids long. In human plasma, they
make up 2% of the total protein amount, of which 70% is
-1-antitrypsin. Both extracellular and intracellular serpins
have been identified (22). Members of the superfamily of serine
protease inhibitors are expressed in a cell-specific manner and
are involved in a number of fundamental biological processes
such as blood coagulation, complement activation, fibrinolysis,
angiogenesis, inflammation, and tumor suppression (23–25).
The protein structure of serpins is usually characterized by
three -sheets (A, B, and C) and eight or nine -helices (26). A
typical feature of serpins is the reactive center loop (RCL),3 a
proteinmotif composed of20 amino acids, located near the C
terminus of the protein. This motif contains a scissile bond
between residues called P1 and P1, which is cleaved by the
target protease. Once cleaved, the RCL domain traps the pro-
tease and moves to the opposite pole of the serpin through the
-sheetA. This tight association results in an irreversible loss of
structure and distortion of both the protease and the serpin.
Inside the RCL domain the hinge region (amino acids P15–P9)
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is implicated in the stabilization of the interactionwith the pro-
tease and provides mobility for the integration of the RCL in
-sheetA. Some serpin familymembers, while structurally sim-
ilar to inhibitor serpins, have no inhibitory functions. These
non-inhibitory serpins include corticosteroid binding globulin
and thyroxine binding globulin, which are involved in hormone
transport, angiotensinogen, which is a peptide hormone pre-
cursor, and ovalbumin. These serpins retain the mobility of the
RCL domain. However, there is no evidence for a conforma-
tional change following cleavage at their putative reactive
centers.
A few serpins have been recently isolated from the hard ticks
Amblyomma hebraeum, Amblyomma variegatum, Boophilus
microplus, Hemaphysalis longicornis, I. scapularis, and Rhipi-
cephalus appendiculatus (27–30). These proteins are mainly
expressed in tick salivary glands and are secreted in the saliva.
Most of them have been proposed as targets in an anti-tick
mixture vaccine (30–32, 34).
Recently, we have characterized a protein, which is up-regu-
lated during the bloodmeal andmodulates both the innate and
acquired immunity of the host (35). Accordingly, we named the
protein Iris for “I. ricinus immunosuppressor.” Iris was also
found to be related to the pig leukocyte elastase inhibitor (35).
In this report, we present the cloning and the expression of Iris
as well as single pointmutants in insect cells. Structural analysis
and directed mutagenesis confirmed that Iris is a serpin with
Met-340 as the P1 residue. We also show that Iris is a specific
elastase inhibitor that interferes with the coagulation pathways
and the fibrinolysis process via the RCL domain. Finally, we
show that Iris inhibits platelet adhesion via another functional
domain. To our knowledge, this is the first ectoparasite serpin
that alters both hemostasis and the immune response.
MATERIALS ANDMETHODS
Plasmid Construction, Protein Expression, and Purification—
The coding sequence for Iris (formerly Seq24; accession num-
ber AJ269658) was subcloned from vector pCDNA3.1-V5-
His/Iris (35) between the KpnI/AgeI restriction sites of vector
pBlueBac4.5-V5-His (Invitrogen) in-frame with the coding
sequence of the V5 andHis epitopes at the C terminus. Recom-
binant baculoviruses were made by recombination between
pBlueBac/Iris and Bac-N-Blue linear DNA virus (Invitrogen).
Recombinant viruses were selected and amplified according to
the manufacturer’s instruction. SF9 cells were infected with a
high titer stock of recombinant baculovirus andwere incubated
for 55 h at 27 °C. Cells were then lysed using the French press,
and spun at 106  g for 40 min. The recombinant protein was
further purified in one step from the cleared supernatant by
chelating chromatography over Ni2-Sepharose (Qiagen).
Recombinant Iris was eluted in 50 mM Tris-HCl (pH 7.5) con-
taining 500 mM NaCl and 150 mM imidazole. All purification
steps were carried out at 4 °C. Typically, 50 mg of purified rIris
was obtained per liter of suspension culture.
Site-directedMutagenesis of Iris in pBlueBac4.5V5His—Mu-
tantswereproducebyusing theQuikChangePCRmutagenesis kit
(Stratagene).The followingPCRprimerswereused togenerateP9,
P2, and P1 mutants, respectively: 5-GCA CAG AGG CTG CAG
CTCCCACTGCCATACCC-3 (forwardA332P), 5-GGGTAT
GGC AGT GGG AGC TGC AGC CTC TGT GC-3 (reverse
A332P); 5-GCC ATA CCC ATT ATG GCG ATG TGC GCG
AGA TTT CC-3 (forward L339A), 5-GGA AAT CTC GCG
CAC ATC GCC ATA ATG GGT ATG GC-3 (reverse L339A);
5-GCCATACCCATTATGTTGCGGTGCGCGAGATTT
CC-3 (forward M340R), 5-GGA AAT CTC GCG CAC CGC
AAC ATA ATG GGT ATG GC-3 (reverse M340R); where the
underlined nucleotides generate the mutation. Supercompetent
XL1-Blue cells were transformed according to themanufacturer’s
instructions, and the plasmids were purified to confirm the
sequencemodifications by sequencing.
Molecular Modeling—Three-dimensional models of Iris
were generated using the homology modeling software Mod-
eler 6.2 (36). To construct a model, the sequence of Iris was
aligned to a homologous sequence whose three-dimensional
structure had been experimentally determined. For that pur-
pose, the Protein Data Bank (PDB) was screened using the Blast
algorithm.-Antitrypsin (PDB code: 1ATU)was selected as the
template for the native model and horse leukocyte elastase
inhibitor (PDB code: 1HLE) for the cleaved model. The per-
centages of identity with Iris are 32 and 42%, respectively, and
the percentages of similarity 51 and 59%, respectively. To fur-
ther examine the homology, the hydrophobic cluster analysis
plots of both sequences were compared. Briefly, the hydropho-
bic cluster analysis method is based on a two-dimensional hel-
ical plot of the sequence and allows detection of hydrophobic
clusters in proteins (37). The stereochemical quality of themin-
imized three-dimensional model was assessed using Procheck
(38). Both models had no residues located in the disallowed
regions of the, angle pairs of the Ramachandran plot, indi-
cating correct stereochemistry. Molecular views were drawn
with WinMGM (39).
A model of the interaction between Iris and a protease was
built using Swissmodel (40). The template was the complex
between trypsin and alaserpin A353K (PDB code: 1K9O). The
Pex algorithm was used to analyze the residues in this interac-
tion. This method extracts numeric and string descriptions of
protein structures from PDB files and lists parameters such as
the dihedral angles, the N–H bond lengths, the secondary
structure, the closest residues in the interaction, and the mini-
mal distance of the interaction (41).
Enzymatic Assays—To assay the inhibition of proteases, Iris
was mixed in a microcuvette with 5–20 l of a protease at an
equimolecular ratio in 50 mM Tris-HCl (pH 7.5) containing
100 mMNaCl. Residual activity was measured by adding 1 ml
of 0.5 mM of an appropriate chromogenic substrate in 50 mM
Tris-HCl, pH 7.5, 100 mM NaCl. The increase in absorbance
at 405 nm over time was measured. Two variants of the assay
were performed: (i) in a first, residual activity was measured
after incubation for 1 h at 37 °C, (ii) in a second, activity was
measured as function of the incubation time. In the former
case, residual activity in the presence of ovalbumin, which is
a serpin with no inhibitory activity, was taken as the 100%
reference point. rIris was tested in the presence of the fol-
lowing subset of enzyme-substrate systems: human throm-
bin and N-benzoyl-Phe-Val-Arg-p-Na; human leukocyte
elastase (HLE) and N-(methoxysuccinyl)-Ala-Ala-Pro-Val-
p-Na; porcine pancreatic elastase (PPE, Roche Applied
2
Science), and N-methoxysuccinyl-Ala-Ala-Pro-Val-p-Na;
human plasmin and N-p-tosyl-Gly-Pro-Lys-p-Na; human fac-
tor Xa and factor Xa chromogenic substrate; recombinant tissue
plasminogen activator (t-PA, Hyphen Biomed, France) and t-PA
chromogenic substrate; and human trypsin and N-benzoyl-Phe-
Val-Arg-p-Na.We also tested two cysteine proteases (papainwith
pGlu-Phe-Leu-p-Na and caspase 3 with N-acetyl-Asp-Glu-Val-
Asp-p-Na) and one human metalloelastase (MMP12 with MMP
chromogenic substrate, Biomol). All products were purchased
from Sigma-Aldrich, unless otherwise indicated.
Measurement of Association Rate Constants—The associa-
tion rate constant (ka) describes the inhibition kinetics of free
serine proteases by serpins. It was determined by mixing pro-
teases and rIris for variable periods of time before addition of
the substrate (0.5 mM), which slows down the association proc-
ess enough to allow measurement of residual enzyme activity
(42). Considering that the dissociation reaction is slow with
respect to the interval of time needed to follow association, the
rate association,d[E]/dt is given by Equation 1 (42).

d[E ]
dt
 ka[E ][I ] (Eq. 1)
The rate of association was either under second order condi-
tions ([E ]0  [I ]0) or pseudo-first order conditions ([I ]0 	
10[E ]0). In the former case, non-linear regression analysis was
used to fit the data to the following second-order equation,
[E ]
[E ]0
(1 [E ]0kat)
(Eq. 2)
where E is the concentration of free enzyme at any time, t, and
E0 is the concentration at t 0. E0 and E are proportional to the
rate of substrate hydrolysis at t 0 and at any time, respectively.
When pseudo-first order rate constants were used, the data
were fitted to the following exponential equation,
[E ] [E ]0e
ka[I ]0t (Eq. 3)
where I0 is the I concentration at t 0.
Clotting Assays—The tests were performed on a pool of cit-
rated platelet-poor human plasma from six healthy, fully
informed, and consenting adult volunteers. Aliquots were
stored at 80 °C until analysis. Recombinant Iris was dialyzed
in phosphate-buffered saline devoid of Ca2 and Mg2. The
effects of 1.5–6M rIris on coagulation time were evaluated on
BCT machine (Dade, Behring). Phospholipids and activators
(Innovin 1/200 for tissue factor, PTT 1/4 for contact phase acti-
vation) were added to 50l of spiked plasma. Clotting time was
recorded after the addition of 50 l of 25 mM CalCl2.
Cell-based clotting time assays were performed by adding 6
M rIris to a mixture of human plasma and the human mono-
cytes THP1 (106 cells/ml final). The mix was then incubated at
37 °C for 5 min. Clotting times were measured after addition of
100 l of 25 mM CaCl2.
Euglobulin Clot Lysis Time—The euglobulin fraction was
prepared as described by Zouaoui Boudjeltia et al. (43).
Briefly, 300 l of acetic acid (0.025%) and 3.6 ml of deionized
water were added to 400 l of pooled human plasma. The
sample was centrifuged at 4.0  103  g for 10 min at 4 °C.
The supernatant was discarded, and the pellet was resus-
pended in 400 l of Hanks’ balanced salt solution (HBSS)
containing increasing concentrations of rIris, with or with-
out added neutrophils (final concentration 5  106 per ml).
Clot formation was started by adding 100 l (1.5 units/ml) of
thrombin. ECLT was measured by a semi-automatic method
using a “Lysis Timer” device (43).
In addition, another testwas performed to exclude the effects
of the interaction of Iris on the cell surface. Cells were incu-
bated with rIris for 1 h and then washed three times in phos-
phate-buffered saline. Washed cells were then resuspended in
HBSS before use in the ECLT test.
Primary Hemostasis—Blood samples were collected from
five healthy, fully informed, and consenting volunteers in 0.13M
citrate vacuum tubes. Global platelet functionwasmeasured on
PFA-100machine (Dade, Behring)with the collagen/epineph-
rine cartridge. This apparatus creates an artificial vessel con-
sisting of a bioactive membrane with a microscopic aperture
(44). The sample (1/10 protein in HBSS and 9/10 anti-coagu-
lated whole blood) was aspirated through a capillary under
steady high shear rates (5000–6000 s1) within 2 h of sample
collection. The presence of the platelet agonist and the high
shear rates result in a platelet plug that gradually occludes the
aperture. The closure time is considered to be the time required
to obtain full occlusion of the aperture.
FIGURE 1. Three-dimensional models of Iris. Three-dimensional structures
of Iris were constructed by homology modeling using as templates homolo-
gousproteinsuncoveredbyProteinDataBank screening.A, uncleavedmodel
based on the structure of -antitrypsin (PDB code: 1ATU), which shares 32%
identity with Iris. B, cleaved model based on the structure of horse leukocyte
elastase inhibitor (PDB code: 1HLE), which shares 40% identity with Iris. C,
model of the interaction based on the structural model of the trypsin-alaser-
pin interaction (33% identity with Iris). -Sheets are in green; -helices are in
red; coil structures are inwhite for Iris and in purple for trypsin.
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Statistical Analyses—SigmaStat
software (Jandel Scientific, Erkrath,
Germany) was used for the analysis.
Data are represented as mean 

S.D. and were evaluated by one-way
ANOVA. The effect of rIris on
platelet adhesion was evaluated by a
Friedman repeated measures analy-
sis of variance on ranks test.
RESULTS
Molecular Modeling—Iris had
previously been found to be similar
to the pig leukocyte elastase inhibi-
tor (35). In addition, membership in
the serpin superfamily was con-
firmed by the high conservation of
consensus residues identified by
Irving and colleagues (45). All con-
served residues among serpins are
also conserved in Iris except for the
replacement of Phe-106 by Tyr, Ile-
134 by Val, Gly-144 by Ser, Leu-288
by Met, and Pro-377 by Leu. Align-
ment of hydrophobic clusters also
supported homologous folds (data
not shown). Therefore, we sought to
build a three-dimensional model of
the entire protein based on the
homology (Fig. 1) using Modeler
(36). To find an accurate template,
PDB was searched using the Blast
algorithm. Horse leukocyte elastase
inhibitor and -antitrypsin both
displaying over 30% identity with
Iris (Fig. 2) were chosen as tem-
plates for themodels corresponding
to the cleaved state and uncleaved
state, respectively (Fig. 1, A and B).
Models were tested with Procheck,
and all the residues were in the
allowed regions of the Ramachand-
ran plot.
The root mean square deviation
(r.m.s.d.) between the uncleaved
model (Fig. 1A) and its template is
0.44 Å (on 363 C). In contrast, the
calculated r.m.s.d. between ovalbu-
min and -antitrypsin is 1.57 Å.
We also compared the predicted
RCL of Iris with the corresponding
amino acid sequence of inhibitory
and non-inhibitory serpins (Fig. 3).
The RCL from Iris was aligned to
the consensus RCL from inhibitory
serpins (46), among these Glu-324, Gly-325, Thr-326, Ala-328,
and Ala-332 were perfectly conserved. All conserved amino
acids essential for the inhibitory function were present in Iris
(Fig. 2). This alignment suggested that Iris has an inhibitory
function based on the presence of methionine 340 adjacent to
the cleavage site (position P1).
FIGURE 2. Alignment of Iris with-antitrypsin and horse leukocyte elastase inhibitor. Amino acid sequence
alignment between -antitrypsin (PDB code: 1ATU) from residue 46 to 418, Iris from residue 1 to 377, and horse
leukocyteelastase inhibitor (PDBcode:1HLE) fromresidue1to344.ThisalignmentwasobtainedusingtheClustalW
algorithm. Dots indicate similar amino acids, and stars indicate identical amino acids. Indents indicate gaps. Con-
serveddomains areboxed. Theopenboxes indicate thepositionof theRCLdomainand thehighly conserved serpin
residues (s3a domain). The shaded box stands for the serpin signature (Prosite code: PS00284) in Iris.
FIGURE 3. Comparison of the RCL amino acid sequence in Iris and other inhibitory and non-inhibitory
serpins.Conserved residues critical for inhibitory activity havebeen identified byHopkins et al. (45). P notation
is from Schechter and Berger (33). X indicates a residue of Iris involved in the interaction with the protease, as
deduced from the model of Iris in interaction with trypsin.
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We further modeled and analyzed the interactions of Iris
with trypsin to find the residues that make contact with the
protease (Fig. 1C). The complex between trypsin and alaserpin
(PDB code: 1K9O) was used as a template for this model. The
r.m.s.d. between alaserpin and Iris is 0.22Å. Using the Pex algo-
rithm, we determined the residues involved in the interaction.
Most of the important residues were located in the RCL, some
specifically in the Hinge region (Fig. 3).
rIris Expression and Purification—The coding sequence of
Iris was cloned in the vector pBlueBac4.5-V5-His (Invitrogen)
in-framewith theV5-His tag, expressed in a baculovirus system
and purified to homogeneity as confirmed by SDS-PAGE (data
not shown). Affinity-purified rIris migrated at an apparent
mass of 48 kDa on a 10% SDS-polyacrylamide gel (data not
shown). This contrasted with an expected molecular weight of
44 kDa and suggested putative posttranslational modifications.
Inhibition of Protease Activity by rIris—We tested the ability
of purified rIris to inhibit various serine proteases derived from
human blood (leukocyte elastase, t-PA, factor Xa, plasmin,
thrombin, and trypsin) or from porcine pancreas (pancreatic
elastase), as well as two human cysteine proteases (caspase-3
and papain), and one human metalloelastase (MMP12).
Recombinant Iriswas incubated for 1 h at 37 °Cwith the various
proteases, and the residual proteolytic activity was measured
using synthetic chromogenic substrates.Most of the serine pro-
teases were inhibited by rIris, as opposed to the two cysteine
proteases and the metalloelastase, which did not show any sig-
nificant drop of activity in presence of rIris (Table 1). From
these data, the serine proteases could be distributed into three
groups: (i) human leukocyte elastase and porcine pancreas ela-
stase with a residual activity of30%; (ii) thrombin, t-PA, and
factor Xa with a residual activity near 70%; and (iii) plasmin
with 100% residual activity (no inhibitory effect of rIris).
To assess the binding kinetics, Iris and the different pro-
teases were allowed to react together either directly in the
presence of the substrate or for shorter variable periods of
time before addition of the substrate. As shown in Fig. 4, the
kinetics and the residual activities observed at the end of the
kinetics are in agreement with the values observed after 1 h
(Table 1). The data allow determination of the affinity rate
constants for the interaction between rIris and the inhibited
proteases. HLE was the most rapidly inhibited with a rate con-
stant (ka 4.3 (
0.64) 106),20 times faster than the pan-
creatic elastase (ka  2.1 (
0.15)  105). Tissue plasminogen
activator and factor Xa were inhibited with an association rate
similar to that of pancreatic elastase; however, only 30% was
inhibited as compared with 60% for the two elastases. Taken
together, these results strongly suggest that rIris is a specific
serine protease inhibitor and that its natural target proteases
are leukocyte elastase and elastase-like serine proteases.
Mutants of rIris—Based on the putative three-dimensional
structure of Iris, positions near or in the RCL domain that
should affect the inhibitory function of Iris were predicted.
Three positions were selected formutagenesis (Fig. 2). The first
is Ala-332 at P9 in the hinge domain mutated to proline. This
mutation was predicted to disrupt the interaction of Iris with
the protease, render the hingemore rigid, and ultimately hinder
the insertion of theRCL into-sheetA. The secondmutantwas
generated by changing Leu-339 (amino acid P2 in the interac-
tion domain) to an alanine. This mutation was predicted to
modify the hydrophobicity and the steric hindrance at that
position in an attempt to alter the interactionwith the protease.
These two mutants were named A332P and L339A, respec-
tively. Both mutants were produced in the baculovirus expres-
sion system and purified as efficiently as the wild-type protein.
In vitro enzymatic assays indicated that these two mutants
completely lost their ability to inhibit any tested protease
except for a weak activity of A332P against HLE (Table 1).
These data strongly suggest that themechanism of rIris activity
FIGURE 4. Inhibition of proteases by Iris as function of the incubation
time. Proteases were incubated at equimolar ratio with rIris for variable peri-
ods of time as indicated on the x-axis before addition of substrate (0.5 mM).
Residual activities indicated by the amount of metabolized substrate are
reported on the y-axis. They weremeasured as absorbance values at 405 nm.
TABLE 1
Affinity constants and inhibition rate of proteases by rIris and its mutants
Proteases were incubated at an equimolar ratio with rIris or its mutants for 1 h at 37 °C. Residual activity in the presence of ovalbumin, a serpin with no inhibitory activity,
is used as the 100% reference point (see “Materials and Methods”). The mutants A332P and L339A were not tested on proteases, which were not inhibited by rIris. Values
are given as mean
 standard deviation of three repeats.
Affinity constant Inhibition
Iris for protease M340R for protease Iris for protease M340R for protease A332P for protease L339A for protease
ka %
HLE 4.7 (
0.64).E6 NDa 70.3 (
4.68) 6.8 (
3.94) 13.5 (
4.68) 2.7 (
8.11)
PPE 2.2 (
0.15).E5 ND 74.5 (
7.32) 2.4 (
5.52) 4.2 (
4.88) 0.0 (
2.44)
t-Pa 2.9 (
0.15).E5 2.1 (
0.07).E4 30.8 (
7.69) 18.8 (
6.25) 2.6 (
4.44) 2.6 (
8.88)
Factor Xa 1.7 (
0.36).E5 1.4 (
0.25).E6 30.4 (
1.50) 68.5 (
3.15) 4.3 (
1.51) 1.7 (
1.51)
Thrombin 2.5 (
0.42).E4 1.3 (
0.45).E5 28.6 (
4.95) 61.8 (
4.95) 5.7 (
4.95) 0.0 (
4.95)
Trypsin 1.5 (
0.42).E4 2.2 (
0.70).E7 11.8 (
1.86) 85.9 (
2.88) 2.5 (
1.04) 3.0 (
1.06)
Plasmin ND 1.2 (
0.25).E5 1.7 (
7.64) 59.2 (
7.84) ND ND
Caspase 3 ND ND 5.9 (
10.19) 5.0 (
7.86) ND ND
Papain ND ND 1.6 (
2.79) 3.0 (
2.51) ND ND
MMP12 ND ND 1.2 (
1.32) 0.2 (
1.67) ND ND
a ND, not determined.
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is of the serpin type. This hypothesis is supported by the pres-
ence of a methionine (Met-340) at the P1 position. To further
test this possibility, this residue was changed to an arginine.
According to Owen et al. (47, 48), this mutation should change
the affinity of Iris for other serine proteases. In vitro enzymatic
assays showed thatmutantM340R lost its ability to inhibit both
human leukocyte and pig pancreatic elastases. More strikingly
this mutant had amuch stronger affinity than the wild-type Iris
for factor Xa (ka 1.4 (
0.25) 106 versus 1.7 (
0.36) 105),
thrombin (ka 1.3 (
0.45) 105 versus 2.5 (
0.42) 104), and
trypsin (ka  2.2 (
0.70)  107 versus 1.5 (
0.42)  104) (see
Table 1). This correlated with an increased inhibitory activity
for these proteases. In addition, themutantM340R remarkably
inhibited plasmin. Finally, we did not observe any change of activ-
ity against the two cysteine proteases and themetalloprotease.
rIris Inhibits the Contact Phase-activated Coagulation
Pathway—Several serine proteases inhibited by Iris are
involved in coagulation. We therefore investigated the effect of
rIris on blood clotting using assays that measure the contact
phase- and the tissue factor-activated coagulation pathways.
An assay designed to monitor the extrinsic coagulation (tissue
factor-activated) detected only a slight increase of the clotting
time upon addition of rIris (6% for 6 M final of rIris). On the
contrary it significantly increased the intrinsic coagulation time
in a dose-dependent manner (Fig. 5). Indeed, addition of 6 M
rIris prolonged the intrinsic (contact phase) coagulation time
by 21%. On the other hand, the M340R mutant was active in
both assays, causing a drastic increase of both intrinsic and
extrinsic coagulation times by 250% (data not shown) and 300%
(Fig. 5), respectively. Finally, mutant L339A lost all activity as
its addition at the same concentration had no effect at all.
rIris Inhibits Fibrinolysis—The ECLT assay was used to
determine the effect of rIris on fibrinolysis. As shown on Fig. 6,
rIris extended the fibrinolysis time in a dose-dependent man-
ner. The presence of rIris (16M) extended fibrinolysis time up
to 39% as compared with the HBSS control (Fig. 6A). We fur-
ther tested the effect of rIris on euglobulin in the presence of
added human leukocytes. As expected, leukocytes decreased
fibrinolysis time (20%) likely due to the release of elastase by
neutrophils. In this cellular setting, rIris increased fibrinolysis
time by 83
 6.3% (Fig. 6B) as opposed to the addition of 16M
mutant L339A,which had no effect on fibrinolysis time, regard-
less of the addition of neutrophils (Fig. 6, A and B). Moreover,
addition of 16 M mutant M340R completely inhibited fibrin-
olysis (data not shown). This effect was drastic, as no fibrinoly-
sis could be detected as long as 72 h after the beginning of the
assay, whereas regular fibrinolysis time was 6 h. Finally, to
determine if this increasewas due to an interaction of Iris on the
cell surface, cells were preincubated for 1 h in the presence of
rIris, washed, and tested in the ECLT assay. In this case, we did
not observe any increase of the fibrinolysis time (data not
shown).
rIris Inhibits Primary Hemostasis—Closure time was meas-
ured with PFA-100, as a reliable indication of the platelet adhe-
sion time. rIris delayed closure time in a dose-dependent man-
ner in four out of the five samples from five healthy adults,
although for one sample, rIris had no effect (Fig. 7). The addi-
tion of 2 M rIris (final concentration) increased platelet adhe-
sion time by 15–30%, an effect also observed with mutants
L339A and M340R.
FIGURE 5. Iris inhibits the contact phase coagulation pathway. Contact
phase-activated coagulation time in the presence of rIris wild-type ormutant
M340R. Values are given as -fold increase comparedwith the HBSS control as
indicated on the x-axis. Mutant L339A lost the anti-protease activity due to a
mutation in the RCL. Clotting time is defined after activation with prothrom-
boplastin time. ANOVA repeated measures was used, p 0.008. *, p 0.05
versus phosphate-buffered saline, Dunnett’s post hoc test.
FIGURE6. Iris inhibits fibrinolysis. ECLT increasedwith rIris concentration.A,
euglobulin fractionwas resuspended in HBSS in the presence of Iris wild type
or mutant at the indicated concentrations. Values are given as the -fold
increase of clot lysis time comparedwith theHBSS control. Mutant L339A lost
the anti-protease activity due to a mutation in the RCL. ANOVA repeated
measures was used, p 0.006. *, p 0.05 versus HBSS, Bonferroni post hoc
test. B, euglobulin fraction was resuspended in HBSS in the presence of dif-
ferent concentrations of rIris wild type or mutants. White blood cells (86%
neutrophils) were added to a final concentration of 5 106 cells/ml. Values
are given as the -fold increase comparedwithHBSS cells control. AACKPV is
a specific inhibitor of leukocyte elastase. Mutant L339A lost the anti-protease
activity due to a mutation in the RCL. Values for M340R could not be pre-
sented because the experiment was stopped after 72 h while still no fibrinol-
ysis couldbeobserved.ANOVA repeatedmeasureswasused,p0.001. *,p
0.05 versus HBSS, Dunnett’s post hoc test.
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DISCUSSION
The modulation of hemostasis by tick saliva is of major
importance in the successful accomplishment of the bloodmeal
(2, 3). Although extensive information is available about the
effects of tick feeding on host blood coagulation, little is known
about the nature of the active factors expressed by tick salivary
glands. Nevertheless, a few anti-hemostatic compounds have
been molecularly characterized in both soft and hard ticks,
including a plateletIIb3 integrin antagonist and inhibitors of
blood coagulation (7–16).
In this work, we have characterized the anti-hemostatic
properties of a protein induced during the tick feeding proc-
ess, which was formerly named Iris for “I. ricinus immuno-
suppressor” due to its immunomodulatory properties (35).
Amino acid sequence comparisons showed that Iris is highly
homologous to the pig leukocyte elastase inhibitor (35). In
addition, the high conservation of amino acid patterns (see Figs.
2 and 3) as well as the presence of the serpin signature (Prosite
code: PS00284) reactive center loop confirm that Iris is a mem-
ber of the serpin superfamily (45). The homology with -antit-
rypsin and horse leukocyte elastase inhibitor allowed us to con-
struct a three-dimensional model of the entire protein. These
studies also support the notion that Iris belongs to the serpin
superfamily with inhibitory function.
Inhibitory serpins are expressed in a cell-specificmanner and
are involved in a wide variety of fundamental biological pro-
cesses such as blood coagulation, complement activation,
fibrinolysis, angiogenesis, inflammation, and tumor suppres-
sion (23–25). Therefore, Iris was expressed as a recombinant
protein and purified to near homogeneity to examine its prop-
erties as an inhibitor of blood coagulation, fibrinolysis, and pri-
mary hemostasis. rIris inhibited serine proteases (HLE, t-PA,
thrombin, and factor Xa) involved in these mechanisms (Table
1). Affinity rate constants and inhibition values demonstrated
that, among these targets, rIris has the highest affinity for
human leukocyte elastase (Fig. 4 and Table 1) as predicted by
the structural studies. These values are very similar to those
published for 1-antitrypsin (49, 50) suggesting that Iris is an
1-antitrypsin-like inhibitor. These results also suggest that
elastase-like proteases are the likely natural targets of Iris.
It is well documented that the inhibitory activity of serpins is
mediated by the RCL domain. This was confirmed by our struc-
tural model, which predicted the interaction between Iris and
serine proteases through the RCL motif. We therefore con-
structed mutants that should alter the RCL motif and could
affect either the anti-proteolytic specificity or the inhibitory
activity of Iris. Thus, we generated onemutant (M340R, located
at position P1 of the RCL domain) to see whether the specificity
changes from elastase to factor Xa and thrombin as predicted.
Relative to Iris, mutant M340R had a 10-fold higher affinity for
factor Xa and thrombin, and 1,000-fold higher affinity for
trypsin. Concomitantly, mutantM340R lost its ability to inhibit
human or pig elastases. Moreover, it gained inhibitory activity
against plasmin. Therefore, mutation of Met-340 into an argi-
nine residue changed our “1-antitrypsin like” to an “anti-
thrombin-like” protein as observed for Pittsburgh factor1-an-
titrypsin (47, 48). We also introduced two point mutations
(A332P and L339A) in the hinge region (position P9) and in
the RCL domain (position P2), respectively, predicted to inval-
idate the protein. In particular, mutant A332P was predicted to
have an altered interaction with the protease as a result of the
stereochemical constraints imposed by the proline ring. It
should render the hinge region more rigid and prevent
the insertion of the RCL domain into -sheet A. As a result, the
reaction should proceed directly to the cleaved product (release
of the RCL domain), and there should be no inhibition of the
protease. Both mutants lost anti-proteolytic activity specific to
serine proteases. We therefore propose that the mechanism of
inhibition of Iris on elastase-like proteases is the “suicidal” type
that involves deformation of the protease and not just a “lock of
the active site” type, as for the traditional inhibitors. Because
none of these inactivemutants exhibited any inhibitory activity,
we subsequently used only L339A to characterize the mode of
action of Iris in experimental hemostatic systems.
Numerous serine proteases are involved in blood coagulation
pathways. In vitro enzymatic assays showed that Iris inhibited
several of these proteases (e.g. factor Xa or thrombin) suggest-
ing that Iris could act as an inhibitor of coagulation. While
monitoring the tissue factor-activated pathway, we did not
observe a significant modification of clotting time by adding
rIris in the presence or absence of THP1 monocytes (data not
shown). However, the contact phase-activated coagulation
time was significantly increased in a dose-dependent manner
by the addition of rIris, whereas mutant L339A lost this effect.
There is therefore a correlation between the anti-protease
activity and an effect on coagulation. The preferred inhibition
of the contact phase-activated pathway over the tissue factor-
activated pathway by rIris is consistent with the current knowl-
edge of the biochemistry of the two pathways. Indeed, the for-
mer is composed mainly of serine proteases such as factors IXa
and XIIa that could be the target of inhibitory serpins while the
tissue factor pathway is naturally inhibited by a kunitz protein
(9) rather than a serpin. However, despite the fact that Iris
inhibited significantly the contact phase-activated coagulation
pathway time, it appeared that Iris was not a powerful antico-
FIGURE 7. Iris increases platelet adhesion time. Platelet adhesion time
increased with rIris concentration. Blood samples were collected from five
healthy volunteers into 0.13M citrated vacuum tubes. Platelet adhesion times
were measured through the closure time ratio with PFA-100 (Dade,
Behring). Sampleswere 1/10 protein inHBSS and 9/10 anti-coagulatedwhole
citrated blood. Values are given as the -fold increase comparedwith theHBSS
control. The time required toobtain full occlusionof the aperture is definedas
the collagen/epinephrine closure time. ANOVA repeatedmeasureswas used,
p 0.001. *, p 0.05 versus control, Bonferroni post hoc test.
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agulant. The mutant M340R that we generated, on the con-
trary, acts like a powerful inhibitor of coagulation. Thismutant,
while displaying no affinity and loosing completely its inhibi-
tory activity to elastases, gained inhibitory activity against fac-
tor Xa and thrombin according to an increase of its affinity
constant to these proteases. Therefore, comparing to the blood
coagulation inhibitory properties of Iris, the mutant M340R
shows an increased inhibitory potential of the surface-activated
coagulation pathway and exhibits new inhibitory activity on the
tissue factor pathway.
Lysis of the fibrin clot also involves several serine proteases,
including plasmin, t-PA, or leukocyte elastase. The calculation
of association second order rates and percentages of inhibition
showed that the t-PA and leukocyte elastase are targets of rIris.
This is consistent with the high degree of sequence identity of
Iris with the human leukocyte elastase inhibitor and with plas-
minogen activator inhibitor type 2. The role of rIris on fibrin-
olysis was therefore evaluated by using the ECLT assay. To
ensure that the increase of fibrinolysis time was not an artifact
due to inhibition of fibrino-formation, the ECLT assay was per-
formed in the presence of a large excess of thrombin. In these
conditions, rIris only inhibited t-PA (Fig. 8). This inhibition
slowed the plasminogen activation and consequently increased
the fibrinolysis time (Fig. 6A). We further tested the effect of
rIris on plasma in the presence of human leukocytes (Fig. 6B).
As expected, leukocytes decreased fibrinolysis time by 20%,
probably due to their secretion of elastase. In that situation, the
action of rIris was accordingly underlined prolonging the
fibrinolysis time by 83%, dramatically exceeding the values
obtained in the absence of neutrophils. In addition, mutant
L339A had no effect on fibrinolysis timewhether in presence or
absence of neutrophils. Taken together, these results strongly
suggest that rIris inhibits fibrinolysis due to its anti-proteolysis
activity via the RCL motif. They indicate that this activity is
mediated by inhibition both of t-PA and the elastase released by
leukocytes (Fig. 8). Finally, M340R increased dramatically its
ability to counteract fibrinolysis, an effect related to a change of
the target. Thus, while M340R lost its activity to t-PA and ela-
stase, it gained activity on plasmin.
We also examined the action of rIris on primary hemosta-
sis. rIris and both RCL mutants (L339A and M340R) pro-
mote a dose-dependent increase of the PFA closure time, a
reliable measure of the platelet adhesion time (Fig. 8). This is
in contrast with the observed effect of rIris on blood coagu-
lation and fibrinolysis, an activity that is indeed lost in the
RCL mutants. Because an intact RCL seems dispensable for
iris action on primary hemostasis, this could be explained by
the presence of exosites (predicted by the receptor binding
domainmethod (51)) that could be involved in an interaction
with other proteins such as the von Willebrand factor and
IIb3 integrin. These proteins are indeed required for
platelet adhesion to components of the vessel wall via
domains (52) that interact with specific regions of proteins
located on endothelial cells. Therefore, Iris could inhibit pri-
mary hemostasis by interacting with proteins involved in
such a mechanism.
We have previously shown that Iris inhibits the secretion of
pro-inflammatory cytokines and suppresses the TH1 host
response (35). We now report that Iris acts as an anticoagulant
and a hypo-fibrinolytic factor by targeting serine proteases,
especially elastase-like proteins. In addition, Iris seems to
hinder platelet adhesion via a mechanism independent of its
enzyme inhibitory activity. Interestingly, the involvement of
Iris in modulation of both the hemostatic and immune systems
is consistent with those modulations caused by tick saliva and
tick salivary gland extracts (2–6).
Blood coagulation and fibrinolysis are powerful barriers to
blood feeding by hematophagous parasites (53). Thus, it is not
surprising to find proteins in tick saliva that are able to inhibit
these two processes. Among key players in these, leukocyte ela-
stase is possibly detrimental to different steps of the ticks’ blood
meal through (i) activation of plasminogen into plasmin, (ii)
hydrolysis of fibrin clots, (iii) activation of a pro-inflammatory
response (54, 55), and (iv) digestion of the extracellular matrix
and destruction of tick’s gut tissues.
Hence, inhibitors of elastase, such as Iris could play a
major role in blood feeding through interference with these
processes. More precisely, it (i) inhibits fibrinolysis, (ii)
could prevent the rejection of the parasites by the host, and
(iii) helps to prevent the disanchoring of tick mouthparts
before the end of feeding or disaggregation of midgut tissues
during ingestion of blood. The expression of Iris is up-regu-
lated during the blood meal with a maximum at day 4 (18),
which is precisely the time when the I. ricinus female starts
to swallow the highest amount of blood (1, 56). At this step,
Iris could both be introduced to the midgut along with the
blood meal and be an important tick countermeasure to a
variety of defense mechanisms developed by the host.
FIGURE 8. A model describing the putative inhibitory actions of iris on
fibrinolysis. The fibrin clot is formedby theprocessing actionof thrombinon
fibrinogen. As soon as the presence of fibrin is detected, the plasminogen is
processed and activated into plasmin by the action of t-Pa. The plasmin then
degrades the fibrin clot. In addition, elastase also plays a role in the degrada-
tion of the fibrin clot. Themajority of the factors implied in the fibrinolysis are
controlled by serpins. Dotted arrows represent activation by a molecule,
dashed arrows represent inhibition, and open arrows were used to represent
activation of a protein. Serine proteases inhibited by rIris are underlined. Iris
homologs are framed. PAI, plasminogen activator inhibitor; u-PA, urokinase
plasminogen activator; LEI, leukocyte elastase inhibitor. IIa and XIIIa corre-
spond to activated factors II and XIII, respectively.
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In conclusion, we have analyzed the anti-hemostatic proper-
ties of a serine protease inhibitor, which could play amajor role
in the completion of the blood meal of ticks. The results indi-
cate that, in addition to being an anti-inflammatory factor and a
modulator of the host immune response (35), Iris is a key factor
in the modulation of host local hemostasis. To our knowledge,
this is the first ectoparasite serpin that alters aspects of both
hemostasis and the immune system. In the near future, we will
investigate the involvement of Iris in the physiology of I. ricinus
during the bloodmeal and to assess its suitability as a candidate
for tick vaccine development.
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